Gilead Said to have discounted the price of its new hepatitis C drug Sovaldi with a number of health insurers after facing criticism for selling the treatment at $1,000/pill - financial press
- Medication said to have a list price of $84K for a 12-week course; Seen as a breakthrough in the treatment of the serious liver disease.